PL3936130T3 - Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu - Google Patents

Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu

Info

Publication number
PL3936130T3
PL3936130T3 PL21178882.3T PL21178882T PL3936130T3 PL 3936130 T3 PL3936130 T3 PL 3936130T3 PL 21178882 T PL21178882 T PL 21178882T PL 3936130 T3 PL3936130 T3 PL 3936130T3
Authority
PL
Poland
Prior art keywords
valbenazine
treatment
dosage regimen
movement disorders
hyperkinetic movement
Prior art date
Application number
PL21178882.3T
Other languages
English (en)
Inventor
Christopher O'brien
Original Assignee
Neurocrine Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences, Inc. filed Critical Neurocrine Biosciences, Inc.
Publication of PL3936130T3 publication Critical patent/PL3936130T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL21178882.3T 2014-05-06 2015-05-06 Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu PL3936130T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06

Publications (1)

Publication Number Publication Date
PL3936130T3 true PL3936130T3 (pl) 2024-06-10

Family

ID=53264772

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15724438T PL3139925T3 (pl) 2014-05-06 2015-05-06 Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu
PL21178882.3T PL3936130T3 (pl) 2014-05-06 2015-05-06 Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL15724438T PL3139925T3 (pl) 2014-05-06 2015-05-06 Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu

Country Status (24)

Country Link
US (3) US20170071932A1 (pl)
EP (3) EP3936130B1 (pl)
JP (4) JP6635945B2 (pl)
KR (5) KR20240011255A (pl)
CN (3) CN112741836A (pl)
AU (1) AU2015256012B2 (pl)
CA (1) CA2947736C (pl)
CY (1) CY1125058T1 (pl)
DK (2) DK3139925T3 (pl)
ES (2) ES2976207T3 (pl)
FI (1) FI3936130T3 (pl)
HR (2) HRP20240459T1 (pl)
HU (2) HUE057839T2 (pl)
IL (1) IL248745B (pl)
LT (2) LT3936130T (pl)
MX (1) MX387625B (pl)
NZ (1) NZ725826A (pl)
PL (2) PL3139925T3 (pl)
PT (2) PT3139925T (pl)
RS (2) RS65359B1 (pl)
RU (1) RU2753740C2 (pl)
SI (2) SI3936130T1 (pl)
SM (2) SMT202400199T1 (pl)
WO (1) WO2015171802A1 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL284874B2 (en) * 2015-10-30 2023-10-01 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
LT3394057T (lt) 2015-12-23 2022-06-27 Neurocrine Biosciences, Inc. Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
EP3473623B1 (en) * 2016-06-29 2020-07-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of nbi-98854, preparation method therefor and use thereof
TW202345829A (zh) * 2016-12-02 2023-12-01 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
WO2018130345A1 (en) 2017-01-10 2018-07-19 Sandoz Ag Crystalline valbenazine free base
KR20230169457A (ko) 2017-01-27 2023-12-15 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CA3054238A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
CA3057543A1 (en) * 2017-04-01 2018-10-04 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
RU2768738C2 (ru) * 2017-04-01 2022-03-24 Адептио Фармасьютикалз Лимитед ПРИМЕНЕНИЕ (-)-α-ДИГИДРОТЕТРАБЕНАЗИНА ИЛИ ЕГО КОМБИНАЦИИ С (+)-α-ДИГИДРОТЕТРАБЕНАЗИНОМ В ЛЕЧЕНИИ ГИПЕРКИНЕТИЧЕСКОГО ДВИГАТЕЛЬНОГО РАССТРОЙСТВА, А ТАКЖЕ СООТВЕТСТВУЮЩИЕ СПОСОБЫ
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
US20200179352A1 (en) * 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
RS66714B1 (sr) 2017-09-21 2025-05-30 Neurocrine Biosciences Inc Formulacija visoke doze valbenazina i sastavi, postupci i kompleti povezani sa njim
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
MX2020003421A (es) * 2017-10-10 2020-07-20 Neurocrine Biosciences Inc Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
CA3081709A1 (en) * 2017-11-08 2019-05-16 Yuhua Li Esters of dihydrotetrabenazine
EP3733666B1 (en) 2017-12-26 2022-09-21 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of valbenazine di-p-toluenesulfonate, preparation method thereof and use thereof
DK3784237T3 (da) * 2018-04-25 2024-01-08 Shinkei Therapeutics Inc Indretning til transdermal levering af tetrabenazin
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
EP3806856A1 (en) 2018-06-14 2021-04-21 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
MA53239A (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
MX2021013132A (es) * 2019-05-09 2021-11-25 Neurocrine Biosciences Inc Metodos para la administracion de ciertos inhibidores del transportador 2 vesicular de monoaminas (vmat2).
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2081929T3 (da) * 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
EP2083744A4 (en) * 2006-11-09 2013-08-28 Univ New York DEGRADED GLASS / ZIRCONIUM / GLASS STRUCTURES FOR DAMAGE-RESISTANT DENTAL AND ORTHOPEDIC CERAMIC PROSTHESES
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
CA2736409C (en) 2008-09-18 2017-07-11 Auspex Pharmaceutical, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
JP2013501810A (ja) * 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
CA2801061A1 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
CA2883641C (en) * 2012-09-18 2021-09-14 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2938581C (en) * 2014-02-07 2023-02-28 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof

Also Published As

Publication number Publication date
HRP20240459T1 (hr) 2024-06-21
FI3936130T3 (fi) 2024-04-23
KR20200133003A (ko) 2020-11-25
KR20220140647A (ko) 2022-10-18
EP3936130B1 (en) 2024-02-14
US20170071932A1 (en) 2017-03-16
WO2015171802A1 (en) 2015-11-12
JP2019218407A (ja) 2019-12-26
JP2021191799A (ja) 2021-12-16
JP2024153782A (ja) 2024-10-29
CN112741836A (zh) 2021-05-04
KR20160147044A (ko) 2016-12-21
ES2976207T3 (es) 2024-07-26
RS62782B1 (sr) 2022-01-31
SI3139925T1 (sl) 2022-04-29
LT3936130T (lt) 2024-04-25
HUE066361T2 (hu) 2024-07-28
EP4389227A3 (en) 2024-09-04
HRP20220025T1 (hr) 2022-04-01
CN106456629A (zh) 2017-02-22
AU2015256012A1 (en) 2016-11-24
PT3139925T (pt) 2022-01-26
US20200101063A1 (en) 2020-04-02
CN112741835A (zh) 2021-05-04
PT3936130T (pt) 2024-04-17
AU2015256012B2 (en) 2020-07-23
SMT202400199T1 (it) 2024-07-09
DK3139925T3 (da) 2021-12-20
EP3936130A1 (en) 2022-01-12
DK3936130T3 (da) 2024-03-25
MX387625B (es) 2025-03-18
RS65359B1 (sr) 2024-04-30
EP3139925A1 (en) 2017-03-15
IL248745A0 (en) 2017-01-31
CY1125058T1 (el) 2023-06-09
LT3139925T (lt) 2022-01-25
JP6635945B2 (ja) 2020-01-29
US20210196702A1 (en) 2021-07-01
KR20250029267A (ko) 2025-03-04
ES2904526T3 (es) 2022-04-05
HUE057839T2 (hu) 2022-06-28
SMT202200193T1 (it) 2022-07-21
IL248745B (en) 2022-07-01
CA2947736A1 (en) 2015-11-12
RU2016147523A3 (pl) 2018-12-28
JP2017514850A (ja) 2017-06-08
EP3139925B1 (en) 2021-12-01
MX2016014429A (es) 2017-04-06
NZ725826A (en) 2023-05-26
CA2947736C (en) 2023-04-18
EP4389227A2 (en) 2024-06-26
PL3139925T3 (pl) 2022-03-21
SI3936130T1 (sl) 2024-05-31
KR20240011255A (ko) 2024-01-25
RU2016147523A (ru) 2018-06-08
RU2753740C2 (ru) 2021-08-23

Similar Documents

Publication Publication Date Title
SI3936130T1 (sl) Režim odmerjanja valbenazina za zdravljenje hiperkinetičnih gibalnih motenj
IL247452A0 (en) Compounds for treatment of complement mediated disorders
IL256166B (en) Compounds for use in treating neuromuscular disorders
IL256175A (en) Using exosomes to treat the disease
LT3206715T (lt) Kanabidiolio naudojimas tuberozinės sklerozės komplekso gydymui
HUE059662T2 (hu) Eljárás terápiás immunsejtek hatékonyságának fokozására
LT3882250T (lt) Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui
MA39483A (fr) Agents thérapeutiques cibles
DK3215607T3 (da) Phagterapi
GB201410816D0 (en) Therapeutic agents
IL249502B (en) New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
DK3363428T3 (da) Perfusionsdoseringsform
IL251904A0 (en) Apilimod for use in the treatment of melanoma
PL3978074T3 (pl) Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1
GB201410815D0 (en) Therapeutic agents
DK3137126T3 (da) Medicinske indretninger med ikke-ensartede coatinger med henblik på forbedret ekkogenicitet
GB201410817D0 (en) Therapeutic agents
DK3215223T3 (da) Buprenorphindoseringsskemaer
DK3126791T3 (da) Doseringsanordning
HUE070257T2 (hu) Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére
HUE046209T2 (hu) Kompozíció porckoronggal összefüggõ fájdalom kezelésében történõ alkalmazásra
DE112015001144A5 (de) Therapievorrichtung
IL249374A0 (en) Pharmaceutical administration forms
TH1601003393A (th) รูปแบบปริมาณที่ให้ทางเภสัชกรรม